ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

3:15PM-3:30PM: Abstract Number: 1687

Body Esteem and Sexual Function in Women with Systemic Lupus Erythematosus

Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

3:15PM-3:30PM: Abstract Number: 1693

Characterizing ANCA-specific B Cells in ANCA-associated Vasculitis

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

3:15PM-3:30PM: Abstract Number: 1711

Dysfunctional Neurobiology Of The Insula Characterizes Fatigue In Psoriatic Arthritis

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

3:15PM-3:30PM: Abstract Number: 1699

Protein-coding Somatic Genetic Variation in Lymphocytes in Systemic Lupus Erythematosus

Abstracts: Genetics, Genomics & Proteomics (1698–1703)

3:15PM-3:30PM: Abstract Number: 1717

The Systemic Lupus International Collaborating Clinics Frailty Index (SLICC-FI) Predicts Mortality In Systemic Lupus Erythematosus (SLE) Patients: Data From The Almenara Lupus Cohort

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

3:30PM-3:45PM: Abstract Number: 1700

Altered Gene Expression In Male SLE Is Mapped To a Male-Specific Y Chromosome Locus Associated with Microdeletions

Abstracts: Genetics, Genomics & Proteomics (1698–1703)

3:30PM-3:45PM: Abstract Number: 1688

Impact of Stress, Anxiety, and Depression on Fatigue as moderated by Resilience and Exposure to Trauma in Rheumatology Patients

Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

3:30PM-3:45PM: Abstract Number: 1718

Mortality and Hematological Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors: Impact of Pre-existing Systemic Lupus Erythematosus

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

3:30PM-3:45PM: Abstract Number: 1694

Obesity Exacerbates Autoimmunity by Dysregulating B Cell Behavior

Abstracts: B Cell Biology & Targets in Autoimmune & Inflammatory Disease (1691–1697)

3:30PM-3:45PM: Abstract Number: 1706

Overcoming Barriers to ANA Testing in Pediatric Populations in Africa

Abstracts: Healthcare Disparities in Rheumatology (1704–1709)

3:30PM-3:45PM: Abstract Number: 1712

Reduced Cardiometabolic Burden and Inflammation in Patients with Psoriatic Arthritis Cared for in a Multi-Disciplinary, Combined Psoriasis-Psoriatic Arthritis Center

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

3:45PM-4:00PM: Abstract Number: 1689

Addressing Perceived Discrimination in Lupus Care: Enhancing Patient Empowerment and Health Equity Through Education and Support

Abstracts: ARP I: Multidimensional Influences on Health in SLE (1686–1691)

3:45PM-4:00PM: Abstract Number: 1713

Diagnostic Delay in Psoriatic Arthritis and its Impact on Radiological Outcomes: A Systematic Review and Meta-analysis of 23,894 Patients

Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Diagnosis, Manifestations, & Outcomes I: Advances in Psoriatic Disease (1710–1715)

3:45PM-4:00PM: Abstract Number: 1701

Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen

Abstracts: Genetics, Genomics & Proteomics (1698–1703)

3:45PM-4:00PM: Abstract Number: 1719

Impact of SGLT2 Inhibitors on Cardiovascular Events, Mortality, and Lupus Nephritis in Patients with Systemic Lupus Erythematosus and Diabetes: Retrospective Cohort Study

Abstracts: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes II: Morbidity & Mortality (1716–1721)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].